Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ENOV 
Enovis Corp (ENOV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ENOV (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $52.2
1 Year Target Price $52.2
| 7 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -38.31% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.75B USD | Price to earnings Ratio - | 1Y Target Price 52.2 |
Price to earnings Ratio - | 1Y Target Price 52.2 | ||
Volume (30-day avg) 11 | Beta 1.81 | 52 Weeks Range 25.47 - 49.83 | Updated Date 08/29/2025 |
52 Weeks Range 25.47 - 49.83 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -14.95 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-07 | When - | Estimate 0.7187 | Actual 0.79 |
Profitability
Profit Margin -37.8% | Operating Margin (TTM) 2.41% |
Management Effectiveness
Return on Assets (TTM) 0.89% | Return on Equity (TTM) -28.25% |
Valuation
Trailing PE - | Forward PE 9.98 | Enterprise Value 3169216373 | Price to Sales(TTM) 0.8 |
Enterprise Value 3169216373 | Price to Sales(TTM) 0.8 | ||
Enterprise Value to Revenue 1.45 | Enterprise Value to EBITDA 22.42 | Shares Outstanding 57159800 | Shares Floating 56426443 |
Shares Outstanding 57159800 | Shares Floating 56426443 | ||
Percent Insiders 1.56 | Percent Institutions 121.2 |
Upturn AI SWOT
Enovis Corp
Company Overview
History and Background
Enovis Corp, formerly DJO Global, is a global medical technology company focused on developing and marketing innovative solutions for musculoskeletal health. Founded in 1981, it has grown through acquisitions and organic development to become a leader in its field.
Core Business Areas
- Reconstructive: Developing and marketing implants and related products for joint reconstruction procedures, including hip, knee, and shoulder replacements.
- Rehabilitation, Prevention & Pain Management: Offering a range of non-surgical products and services for rehabilitation, pain management, and injury prevention, including bracing, supports, and physical therapy equipment.
Leadership and Structure
The company is led by CEO Matt Trerotola. Enovis operates with a functional organizational structure, with global business units reporting to the executive leadership team.
Top Products and Market Share
Key Offerings
- DJO Surgical: Joint reconstruction implants, including hip, knee, and shoulder systems. Competitors include Zimmer Biomet (ZBH), Stryker (SYK), and Johnson & Johnson (JNJ). Market share data is difficult to obtain precisely due to variations in product categories and geographies, but Enovis holds a significant position in specific segments.
- DonJoy Bracing: Braces and supports for injury prevention and rehabilitation. Competitors include BREG, u00d6ssur, and Bauerfeind. DonJoy is a recognized brand in sports medicine bracing, holding a substantial market share within this category.
- MotionMD: Integrated solutions for surgical and non-surgical care that connects patients with providers. Competitors include Wellsky, Cerner, Allscripts, and Epic. Market share data is difficult to obtain due to variation of product categories and geographies, but Enovis holds a position of growth within this segment
Market Dynamics
Industry Overview
The musculoskeletal health market is driven by an aging population, increasing prevalence of obesity, and growing demand for minimally invasive surgical procedures. It is a large and growing market with significant innovation and competition.
Positioning
Enovis holds a leading position in the musculoskeletal market, offering a broad portfolio of products and services across surgical and non-surgical segments. Its competitive advantages include a strong brand reputation, established distribution network, and focus on innovation.
Total Addressable Market (TAM)
The global musculoskeletal market is estimated to be worth hundreds of billions of dollars. Enovis is positioned to capture a significant share of this market through its diversified product portfolio and global reach.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Diversified product portfolio
- Global distribution network
- Focus on innovation
- Strong financial position
Weaknesses
- Exposure to regulatory risks
- Dependence on third-party suppliers
- Integration risks associated with acquisitions
- Susceptible to price pressure from competitors
- Reliance on hospitals and physicians
Opportunities
- Expanding into emerging markets
- Developing new technologies and products
- Acquiring complementary businesses
- Partnering with healthcare providers
- Growing demand for non-surgical solutions
Threats
- Increasing competition
- Changes in reimbursement policies
- Economic downturns
- Product liability claims
- Technological obsolescence
Competitors and Market Share
Key Competitors
- ZBH
- SYK
- JNJ
- BSX
- MRK
Competitive Landscape
Enovis competes effectively with larger players by focusing on specific market segments and delivering innovative solutions. Its competitive disadvantages are mostly in comparison with companies which are larger than themselves in terms of total market valuation.
Major Acquisitions
Innate Device, Inc.
- Year: 2024
- Acquisition Price (USD millions): 145
- Strategic Rationale: Strategic reasons include to expand the company's foot and ankle business. Innate Device brings an innovative portfolio of differentiated foot and ankle products with a strong focus on flatfoot reconstruction.
Growth Trajectory and Initiatives
Historical Growth: Requires access to real-time financial data. This will be updated if provided with an option to update.
Future Projections: Requires access to real-time financial data. This will be updated if provided with an option to update.
Recent Initiatives: Recent initiatives include strategic acquisitions to expand product offerings and market reach, as well as investments in research and development to drive innovation.
Summary
Enovis is a strong medical technology company with a diverse product portfolio and a focus on innovation. The company operates in a growing market and has a solid track record of growth. However, Enovis faces competition from larger players and is exposed to regulatory and economic risks. Strategic acquisitions and focus on emerging markets are critical for sustained growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Market Research Reports
- Analyst Estimates
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market data and estimates are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Enovis Corp
Exchange NYSE | Headquaters Wilmington, DE, United States | ||
IPO Launch date 2008-05-08 | CEO & Director Mr. Damien McDonald | ||
Sector Healthcare | Industry Medical Devices | Full time employees 7367 | Website https://www.enovis.com |
Full time employees 7367 | Website https://www.enovis.com | ||
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The company's Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. Its Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. It distributes its products through independent distributors and directly under the ESAB and DJO brands. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.